In this issue:
Recommended dose of AFM13-NK
Zanubrutinib plus venetoclax
Toxicity of acalabrutinib plus bendamustine-rituximab
Efficacy and safety of glofitamab
Safety of FT516 fore relapse/refractory B-cell lymphoma
Isatuximab plus cemiplimab
Impact of RDI of VCR
Value of MRD on ctDNA
Investigating outcomes of primary vitreoretinal lymphoma
CAR-T therapy versus auto-HCT
Please login below to download this issue (PDF)